Zilucoplan is under clinical development by UCB and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zilucoplan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zilucoplan overview

Zilucoplan (Zilbrysq) acts as an immunosuppressive agent. It is formulated as solution for subcutaneous route of administration. Zilbrysq is indicated for the treatment of generalized myasthenia gravis.

Zilucoplan is under development for the treatment of atypical hemolytic uremic syndrome, lupus nephritis, amyotrophic lateral sclerosis, renal disorder  and generalized myasthenia gravis. The drug candidate is administered through the subcutaneous route. The drug candidate is synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated like. It acts by targeting complement C5. It was also under development for paroxysmal nocturnal hemoglobinuria (PNH).

It was under development for the treatment of immune-mediated necrotizing myopathy (Autoimmune-musculoskeletal disorder), Coronavirus disease 2019 (COVID-19) patients with acute hypoxic respiratory failure.

UCB overview

UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, Germany, Italy, Spain, France, China, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

For a complete picture of Zilucoplan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.